Magnetohydrodynamic thermochemotherapy and MRI of mouse tumors (original) (raw)
Related papers
Pharmaceutical Chemistry Journal, 2008
Intravenous administration of dextran-ferrite sol was used to amplify T 2 -weighed echo gradient (500/15) scanning MR images with visualization of the invasion margins of tumor cells into healthy tissues, along with macro-and micrometastases, in animals with lymphocytic leukemia and Ehrlich and Lewis carcinomas. Magnetohydrodynamic thermochemotherapy (MTCT) using a cyclophosphamide-containing magnetic fluid (saturation magnetization (M s ) 8.6 kA/m, pH 7.4, z + 13 mV) at 46°C for 30 min in an alternating magnetic field (0.88 MHz, 7.2 kA/m, 0.15 kW) with aspiration of necrotic material (ANM) produced regression of P388 tumors of volume~110 mm 3 in BDF1 mice prior to metastasis by 40%, with an increase in lifetime (ILT) of 310%; in tumors of volume~330 mm 3 after metastasis and MTCT-ANM with cyclophosphamide pretreatment, ILT was 220%. 157 0091-150X/08/4204-0157
MRI‐Adaptive Magneto‐Thermo‐Chemotherapy for Improved Cancer Treatment
AIP Conference …, 2010
Dextran-ferrite (DF) has been synthesized and tested as magnetic resonance imaging (MRI) negative contrast agent for tumors, invasions and metastases. MRI-adaptive Magneto-thermo-chemotherapy (MTCT) by cisplatin (CP), melphalan (MP) and DF led to improved cancer treatment. MTCT by using AC magnetic field (0.88 MHz, 7.3 kA/m and 0.15 kW) was performed at early stages of oncogenesis at +46ºC for 30 min using DF at a dose of 60 mg Fe/kg containing CP or MP. MTCT led to regression of adenocarcinoma Ca-755 tumor ~45 mm 3 before metastases in female mice up to 40% and increasing of life span up to 280%. As for tumor ~300 mm 3 , the use of MTCT with slime aspiration and the invasions of cyclophosphamide into metastases led to 200% increased life span.
Journal of Magnetism and Magnetic Materials, 2001
Magnetic #uid hyperthermia (MFH) selectively heats up tissue by coupling alternating current (AC) magnetic "elds to targeted magnetic #uids, so that boundaries of di!erent conductive tissues do not interfere with power absorption. In this paper, a new AC magnetic "eld therapy system for clinical application of MFH is described. With optimized magnetic nanoparticle preparations it will be used for target-speci"c glioblastoma and prostate carcinoma therapy.
Pharmaceutical Research, 2014
Purpose Tumor cells can be effectively inactivated by heating mediated by magnetic nanoparticles. However, optimized nanomaterials to supply thermal stress inside the tumor remain to be identified. The present study investigates the therapeutic effects of magnetic hyperthermia induced by superparamagnetic iron oxide nanoparticles on breast (MDA-MB-231) and pancreatic cancer (BxPC-3) xenografts in mice in vivo. Methods Superparamagnetic iron oxide nanoparticles, synthesized either via an aqueous (MF66; average core size 12 nm) or an organic route (OD15; average core size 15 nm) are analyzed in terms of their specific absorption rate (SAR), cell uptake and their effectivity in in vivo hyperthermia treatment. Results Exceptionally high SAR values ranging from 658± 53 W*g Fe −1 for OD15 up to 900±22 W*g Fe −1 for MF66 were determined in an alternating magnetic field (AMF, H=15.4 kA*m −1 (19 mT), f=435 kHz). Conversion of SAR values into systemindependent intrinsic loss power (ILP, 6.4±0.5 nH*m 2 *kg −1 (OD15) and 8.7±0.2 nH*m 2 *kg −1 (MF66)) confirmed the markedly high heating potential compared to recently published data. Magnetic hyperthermia after intratumoral nanoparticle injection results in dramatically reduced tumor volume in both cancer models, although the applied temperature dosages measured as CEM43T90 (cumulative equivalent minutes at 43°C) are only between 1 and 24 min. Histological analysis of magnetic hyperthermia treated tumor tissue exhibit alterations in cell viability (apoptosis and necrosis) and show a decreased cell proliferation. Conclusions Concluding, the studied magnetic nanoparticles lead to extensive cell death in human tumor xenografts and are considered suitable platforms for future hyperthermic studies. KEY WORDS CEM43T90 . in vivo . iron oxide nanoparticles . magnetic hyperthermia . temperature dose ABBREVIATIONS AMF Alternating magnetic field CEM43 Cumulative equivalent minutes at 43°C CEM43T90 Cumulative equivalent minutes at a T90 temperature of 43°C ILP Intrinsic loss power MNP Magnetic nanoparticles SAR Specific absorption rate T90 Temperature exceeded by 90% of the tumor surface
Perspective of Magnetic Fluid Hyperthermia (MFH) for the Treatment of Tumor
Journal of Tumor Research
The localized heating of tumor in Magnetic Fluid Hyperthermia (MFH) enables it to be a superior way of treatment than other conventional treatment of tumors. In combination with chemotherapy, radiation therapy and surgery, better results have been achieved and thus made it clinically approvable. This article introduces recent advances of magnetic materials used in magnetic fluid hyperthermia, factors affecting the performances of these particles and the future of this therapy.
In this chapter we review both preformulation and formulation efforts relevant to magnetically-induced hyperthermia as a new and attractive modality for the treatment of cancer lesions eligible for a thermotherapy. Also addressed are the efforts to apply this method to de novo indications in specific clinical situations. Following a pharmaceutical approach, we first introduce the general biological rationale for the use of hyperthermia, considering the techniques available to generate hyperthermia. We then detail several different magnetically-induced heating modalities and review the literature on formulations in an attempt to compare their specificities, advantages and shortcomings. First, we consider the formulation of glass ceramics and cement biomaterials for magnetically mediated hyperthermia with respect to the biological specificities in the treatment of solid bone tumors. Secondly, formulations intended for magnetically mediated hyperthermia are considered for soft tissue solid tumors, emphasizing the potential for pharmacological modulation. In the final section, we consider magnetic liposome formulations that can be equally administrated in various types of tumors. We do not detail magnetic fluid hyperthermia that uses suspensions of magnetic nanoparticles stabilized by various coatings. Biological and immunological considerations revealed by liposomes are outlined. This chapter focuses on the importance of the formulation and on
Comprehensive understanding of magnetic hyperthermia for improving antitumor therapeutic efficacy
Theranostics
Magnetic hyperthermia (MH) has been introduced clinically as an alternative approach for the focal treatment of tumors. MH utilizes the heat generated by the magnetic nanoparticles (MNPs) when subjected to an alternating magnetic field (AMF). It has become an important topic in the nanomedical field due to their multitudes of advantages towards effective antitumor therapy such as high biosafety, deep tissue penetration, and targeted selective tumor killing. However, in order for MH to progress and to realize its paramount potential as an alternative choice for cancer treatment, tremendous challenges have to be overcome. Thus, the efficiency of MH therapy needs enhancement. In its recent 60-year of history, the field of MH has focused primarily on heating using MNPs for therapeutic applications. Increasing the thermal conversion efficiency of MNPs is the fundamental strategy for improving therapeutic efficacy. Recently, emerging experimental evidence indicates that MNPs-MH produces nano-scale heat effects without macroscopic temperature rise. A deep understanding of the effect of this localized induction heat for the destruction of subcellular/cellular structures further supports the efficacy of MH in improving therapeutic therapy. In this review, the currently available strategies for improving the antitumor therapeutic efficacy of MNPs-MH will be discussed. Firstly, the recent advancements in engineering MNP size, composition, shape, and surface to significantly improve their energy dissipation rates will be explored. Secondly, the latest studies depicting the effect of local induction heat for selectively disrupting cells/intracellular structures will be examined. Thirdly, strategies to enhance the therapeutics by combining MH therapy with chemotherapy, radiotherapy, immunotherapy, photothermal/photodynamic therapy (PDT), and gene therapy will be reviewed. Lastly, the prospect and significant challenges in MH-based antitumor therapy will be discussed. This review is to provide a comprehensive understanding of MH for improving antitumor therapeutic efficacy, which would be of utmost benefit towards guiding the users and for the future development of MNPs-MH towards successful application in medicine.
Cancer therapy using magnetic hyperthermia
2014
Abstract: The efficient targeting and therapeutic efficacy of a combination of drugs (curcumin and 5-Fluorouracil [5FU]) and magnetic nanoparticles encapsulated poly(D,L-lactic-co-glycolic acid) nanoparticles, functionalized with two cancer-specific ligands are discussed in our work. Read this original research and sign up to receive International Journal of Nanomedicine here: http://www.dovepress.com/articles.php?article\_id=15449